154 related articles for article (PubMed ID: 20820193)
1. Structural basis of immunosuppression by the therapeutic antibody daclizumab.
Yang H; Wang J; Du J; Zhong C; Zhang D; Guo H; Guo Y; Ding J
Cell Res; 2010 Dec; 20(12):1361-71. PubMed ID: 20820193
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for the blockage of IL-2 signaling by therapeutic antibody basiliximab.
Du J; Yang H; Zhang D; Wang J; Guo H; Peng B; Guo Y; Ding J
J Immunol; 2010 Feb; 184(3):1361-8. PubMed ID: 20032294
[TBL] [Abstract][Full Text] [Related]
3. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab.
Binder M; Vögtle FN; Michelfelder S; Müller F; Illerhaus G; Sundararajan S; Mertelsmann R; Trepel M
Cancer Res; 2007 Apr; 67(8):3518-23. PubMed ID: 17440057
[TBL] [Abstract][Full Text] [Related]
4. The fractional excretion of soluble interleukin-2 receptor-alpha is an excellent predictor of the interleukin-2 receptor-alpha status after treatment with daclizumab.
ter Meulen CG; Jacobs CW; Wetzels JF; Klasen IS; Hilbrands LB; Hoitsma AJ
Transplantation; 2004 Jan; 77(2):281-6. PubMed ID: 14742994
[TBL] [Abstract][Full Text] [Related]
5. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?
Van Gelder T; Warlé M; Ter Meulen RG
Drugs; 2004; 64(16):1737-41. PubMed ID: 15301558
[TBL] [Abstract][Full Text] [Related]
6. Effect of anti-IL-2Ralpha antibody on IL-2-induced Jak/STAT signaling.
Tkaczuk J; Yu CL; Baksh S; Milford EL; Carpenter CB; Burakoff SJ; McKay DB
Am J Transplant; 2002 Jan; 2(1):31-40. PubMed ID: 12095053
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation.
Koch M; Niemeyer G; Patel I; Light S; Nashan B
Transplantation; 2002 May; 73(10):1640-6. PubMed ID: 12042653
[TBL] [Abstract][Full Text] [Related]
8. Daclizumab.
Mottershead M; Neuberger J
Expert Opin Biol Ther; 2007 Oct; 7(10):1583-96. PubMed ID: 17916050
[TBL] [Abstract][Full Text] [Related]
9. The use of antibodies against the IL-2 receptor in transplantation.
Waldmann TA; O'Shea J
Curr Opin Immunol; 1998 Oct; 10(5):507-12. PubMed ID: 9794841
[TBL] [Abstract][Full Text] [Related]
10. [Daclizumab and basiliximab: monoclonal mouse-man antibodies with effective immunosuppression without side effects].
ter Meulen CG; Hilbrands LB; van Riemsdijk-van Overbeeke IC; Hené RJ; Christiaans MH; Hoitsma AJ
Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2396-400. PubMed ID: 11145094
[TBL] [Abstract][Full Text] [Related]
11. Extended daclizumab monotherapy for rejection-free survival in non-adherent adolescent recipients of renal allografts.
Chaudhuri A; Salvatierra O; Sarwal MM
Pediatr Transplant; 2009 Nov; 13(7):927-32. PubMed ID: 19017291
[TBL] [Abstract][Full Text] [Related]
12. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
[TBL] [Abstract][Full Text] [Related]
13. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Waldmann TA
J Clin Immunol; 2007 Jan; 27(1):1-18. PubMed ID: 17216565
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive [correction of immunosupressive] agents and their actions.
First MR
Transplant Proc; 2002 Aug; 34(5):1369-71. PubMed ID: 12176401
[No Abstract] [Full Text] [Related]
15. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J
N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817
[TBL] [Abstract][Full Text] [Related]
16. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody.
Beniaminovitz A; Itescu S; Lietz K; Donovan M; Burke EM; Groff BD; Edwards N; Mancini DM
N Engl J Med; 2000 Mar; 342(9):613-9. PubMed ID: 10699160
[TBL] [Abstract][Full Text] [Related]
17. [Monoclonal interleukin-2 receptor antibodies and their use in clinical kidney transplantation: basiliximab and daclizumab].
Madsen M; Svendsen UG
Ugeskr Laeger; 2000 Oct; 162(42):5648-52. PubMed ID: 11059309
[TBL] [Abstract][Full Text] [Related]
18. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Bielekova B; Catalfamo M; Reichert-Scrivner S; Packer A; Cerna M; Waldmann TA; McFarland H; Henkart PA; Martin R
Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5941-6. PubMed ID: 16585503
[TBL] [Abstract][Full Text] [Related]
19. The role of anti-IL-2 receptor in high-risk kidney transplant patients.
Jirasiritham S; Sumethkul V; Mavichak V; Lertsithichai P; Jirasiritham S
Transplant Proc; 2004 Sep; 36(7):2110-2. PubMed ID: 15518764
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy.
Lietz K; John R; Beniaminovitz A; Burke EM; Suciu-Foca N; Mancini DM; Edwards NM; Itescu S
Transplantation; 2003 Mar; 75(6):781-7. PubMed ID: 12660501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]